A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-06821497

2023-508371-36-00 Protocol C2321007 Human pharmacology (Phase I) - Other Ended

Start 15 Jul 2024 · End 12 Nov 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol C2321007

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 6
Countries 1
Sites 1

small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), follicular lymphoma (FL)

Key facts

Sponsor
Pfizer Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 Jul 2024 → 12 Nov 2024
Decision date (initial)
2024-05-28
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), follicular lymphoma (FL)

VersionLevelCodeTermSystem organ class
21.1 LLT 10076506 Castration-resistant prostate cancer 10029104
21.1 PT 10041067 Small cell lung cancer 100000004864
24.0 PT 10085128 Follicular lymphoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation
Pfizer Inc.
Address
66 Hudson Boulevard East
City
New York
Postcode
10001-2189
Country
United States

Scientific contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Public contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 6 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-07-15 2024-11-11 2024-07-18 2024-09-19

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-02 Netherlands Acceptable
2024-05-28
2024-05-28
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-06-03 Netherlands Acceptable
2024-05-28
2024-06-03
3 SUBSTANTIAL MODIFICATION SM-1 2024-06-25 Netherlands Acceptable
2024-07-08
2024-07-08